<DOC>
	<DOCNO>NCT00242567</DOCNO>
	<brief_summary>This study aim determine whether early treatment zoledronic acid , give early phase advance prostate cancer , efficacious delay treatment</brief_summary>
	<brief_title>Study Zoledronic Acid Patients With Hormone-sensitive Bone Metastases From Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>prostate cancer least one bone metastasis receive receive androgen deprivation therapy ( ADT ) previous ADT failure previous current treatment another boneprotecting agent , chemotherapy target therapy abnormal renal function Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>zoledronic acid</keyword>
	<keyword>bone metastasis</keyword>
	<keyword>prostate cancer</keyword>
	<keyword>hormone-sensitive</keyword>
</DOC>